PCMA Says Competition Is Key to Lowering Drug Prices
Competition is the key to lower drug costs, the Pharmaceutical Care Management Association (PCMA) said in a letter to lawmakers in defense of pharmacy benefit managers. Source: Drug Industry Daily
Competition is the key to lower drug costs, the Pharmaceutical Care Management Association (PCMA) said in a letter to lawmakers in defense of pharmacy benefit managers. Source: Drug Industry Daily
Drugmakers were conspicuously absent on Tuesday from two drug pricing hearings on Capitol Hill, where lawmakers called out big pharma for setting high drug prices through manipulative means — and…
A New York pharmacist group claims the misuse of “spread pricing” by the state’s pharmacy benefit managers has led to increased drug prices – especially for generics. Source: Drug Industry…
PhRMA picked holes in a proposed Centers for Medicare & Medicaid Services rule increasing Medicare Advantage and Part D plans’ power to negotiate drug prices. Source: Drug Industry Daily
FDA Commissioner Scott Gottlieb on Monday outlined the agency’s plans for promoting the use of real world evidence in clinical trials in 2019. Source: Drug Industry Daily
Contract manufacturer Thatcher Company failed to exercise appropriate controls over computers and related systems to assure that changes in production were only instituted by authorized personnel, FDA inspectors found during…
Lax medical device reporting and CAPA procedures as well as a host of other quality issues were uncovered during a July 31 to Aug. 2 FDA inspection of LED Intellectual…
FDA inspectors found shoddy process controls and a lack of validation documentation in a Sept. 17 to Sept. 21 inspection of Footprint Medical’s San Antonio, Texas facility. Source: The GMP…
Health Canada released guidance for devicemakers on how to comply with premarket cybersecurity requirements. Source: The GMP Letter
International medical device associations rejected a recent report by the International Consortium of Investigative Journalists (ICIJ), which pointed to inadequate oversight of devices globally. Source: The GMP Letter